Don’t Miss It: Put (BSEM) on Your Radar Tonight and Watch for the Morning Bell

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Krypton Street Just Added BioStem Technologies Inc. (BSEM) To Its Watchlist For Tomorrow—Thursday, April 2, 2026 Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Expect Full Coverage On (BSEM) To Start When The Bell Rings Put (BSEM) On Your Radar Before Tomorrow Morning… April 1, 2026 Don't Miss It | Put (BSEM) on Your Radar Tonight and Watch for the Morning Bell Dear Reader, At Krypton Street, we pay close attention when a small healthcare name starts checking multiple boxes at once. In regenerative medicine, the companies beginning to stand out are the ones pairing real commercial traction with specialized technology and expanding market reach. That's especially true when the business is already generating revenue, posting unusually strong margins, and broadening its footprint through a meaningful acquisition. When those pieces start lining up together, it tends to put a company on more screens in a hurry. BioStem Technologies Inc. (BSEM) is one of the names now starting to fit that profile. The company recently reported $10.1M in fourth-quarter 2025 revenue alongside a robust 97% gross margin, while also finalizing the $40M acquisition of BioTissue's surgical and wound assets as of January 21, 2026. And these are just some of the reasons why (BSEM) has just hit our radar and will be topping our watchlist tomorrow morning—Thursday, April 2, 2026. We'll have all eyes on (BSEM) as soon as the bell rings. But keep in mind, (BSEM) has less than 13M shares listed as available to the public right now. When companies have small public floats like this, the potential exists for big moves if demand begins to shift. In fact, Brad Sorensen of Zacks SCR has set a $25.50 target on (BSEM), which suggests over 580% upside potential from its recent $3.72 range. So before this story moves any further, it's worth taking a closer look at what BioStem Technologies Inc. (BSEM) actually is, what it has built, and why more attention may be starting to find its way here. A Regenerative Medicine Innovator BioStem Technologies Inc. (OTC: BSEM) is a publicly traded, biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies, which are specifically designed to optimize the preservation of the natural properties of perinatal tissues. These technologies support the use of allografts in clinical settings across a wide range of specialties, from chronic wound care to complex surgical procedures. The company's operations are headquartered in Pompano Beach, Florida, where it maintains a quality management system accredited by the American Association of Tissue Banks (AATB). BioStem's growing portfolio of high-quality brands includes its Neox®, Clarix®, VENDAJE®, and American Amnion™ product lines, providing clinicians with a versatile toolkit for regenerative therapies. Strategic Expansion and Market Scaling In early 2026, BioStem Technologies Inc. (BSEM) completed the transformative acquisition of BioTissue's surgical and wound assets for up to $40M, a move that immediately added the Neox and Clarix product families to its portfolio. This acquisition has provided the company with an established entry point into hospital inpatient/outpatient and Ambulatory Surgery Center (ASC) channels. To maximize efficiency, BioStem has initiated a tech-transfer plan to move the manufacturing of these acquired products to its Pompano Beach facility by mid-Q1 2027, targeting gross margins of over 80% over the long term. The company is also deeply committed to an evidence-based clinical strategy to drive long-term adoption. BioStem recently reported results from a randomized controlled trial (RCT) showing the superiority of its BioRetain product versus the standard of care for diabetic foot ulcers (DFU). Furthermore, top-line results from a venous leg ulcer (VLU) trial are expected by mid-2026, which the company anticipates will support further hospital value-analysis approvals and broader payer coverage. Navigating Regulatory and Reimbursement Shifts The regenerative medicine landscape faced significant headwinds in early 2026 due to changes in CMS (Centers for Medicare & Medicaid Services) reimbursement policies for the physician office setting. These changes led to a sharp decline in physician office volume across the industry. However, BioStem's strategic pivot toward the hospital and surgical markets through the BioTissue acquisition serves as a critical hedge against these outpatient reimbursement fluctuations. By focusing on clinically validated products like VENDAJE, management believes the company is well-positioned for the 2027 coverage cycle. The current market shift favors companies that prioritize clinical benefit over price competition, and BioStem's ongoing investment in RCTs is designed to secure "covered" status under new CMS payment environments. Corporate Evolution and Financial Transparency On March 30, 2026, BioStem reached a major corporate milestone by filing its audited consolidated financial statements for fiscal years 2024 and 2025. This filing is a foundational requirement for the company's stated goal of an uplist to Nasdaq. Chairman and CEO Jason Matuszewski emphasized that a Nasdaq listing remains a "top priority" to increase visibility, improve stock liquidity, and provide a more precise market valuation for the company. The addition of a new CFO, auditor, and audit committee chair further underscores the company's commitment to institutional-grade governance. As BioStem transitions from a little-known company into a more mature biotech entity, these structural improvements are intended to attract a broader range of sophisticated investors. Recent Developments March 31, 2026: BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference March 30, 2026: BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 March 24, 2026: BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results March 23, 2026: BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair February 03, 2026: BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research January 21, 2026: BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business 7 Reasons Why (BSEM) Will Be Topping Our Watchlist Tomorrow Morning —Thursday, April 2, 2026… 1. Tight Float: With fewer than 13M shares available to the public, (BSEM) has a limited public float that can draw added attention when demand shifts. 2. Analyst Target: As of February 2026, one analyst places a $25.50 target on (BSEM), implying over 580% upside potential from its recent $3.72 range. 3. Revenue Base: Unlike many early-stage peers, (BSEM) is already generating revenue, including $10.1M in fourth-quarter 2025 sales. 4. Strong Margins: BioStem reported a 97% gross margin, giving (BSEM) a financial profile that stands out in its category. 5. Major Acquisition: In January 2026, (BSEM) completed a BioTissue asset purchase for up to $40M, adding the Neox and Clarix product families. 6. Clinical Validation: Recent trial results showed BioRetain from (BSEM) outperformed standard care in diabetic foot ulcers. 7. Nasdaq Path: With audited financials now filed, (BSEM) has taken a key step toward its stated goal of a Nasdaq uplisting. Put (BSEM) On Your Radar Before Tomorrow Morning… When you step back and look at the full picture, it becomes easier to understand why (BSEM) is getting our attention right now. The company combines a small public float with a clear revenue base, reporting $10.1M in Q4 2025, while maintaining an exceptional 97% gross margin that sets it apart from many peers. Layer in the $40M BioTissue acquisition, which expands its reach into hospital channels, along with clinical data showing superior outcomes, and the foundation starts to look increasingly well-defined. Add to that an analyst target of $25.50 and recent progress toward a Nasdaq uplisting, and you have multiple factors converging at the same time. We will have all eyes on (BSEM) tomorrow morning. Take a look at (BSEM) before you call it a night. Also, keep a lookout for my morning update, it should be coming before the bell rings. Have a good night. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter   KryptonStreet.com ("KryptonStreet" or "KS" ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/01/2026 and ending on 04/02/2026 to publicly disseminate information about (BSEM:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Media 1717 LLC has been paid twenty nine thousand USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Sideways Frequency LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (BSEM:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/bsem-cWqmq/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by alex@kryptonstreet.com